Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 10.82% and Operating profit at 10.36% over the last 5 years
2
Negative results in Dec 25
3
With ROE of 13.09%, it has a very attractive valuation with a 3.69 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 13,732 Million (Large Cap)
28.00
NA
2.31%
-0.41
10.81%
2.86
Revenue and Profits:
Net Sales:
405 Million
(Quarterly Results - Mar 2026)
Net Profit:
94 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.4%
0%
-8.4%
6 Months
-9.19%
0%
-9.19%
1 Year
-6.39%
0%
-6.39%
2 Years
0.7%
0%
0.7%
3 Years
-5.66%
0%
-5.66%
4 Years
-5.89%
0%
-5.89%
5 Years
-4.24%
0%
-4.24%
Tibet Cheezheng Tibetan Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.82%
EBIT Growth (5y)
10.36%
EBIT to Interest (avg)
9.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.39
Tax Ratio
10.20%
Dividend Payout Ratio
34.61%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.58%
ROE (avg)
15.58%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
3.69
EV to EBIT
22.04
EV to EBITDA
17.77
EV to Capital Employed
5.29
EV to Sales
5.44
PEG Ratio
NA
Dividend Yield
2.91%
ROCE (Latest)
23.99%
ROE (Latest)
13.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
405.30
403.00
0.57%
Operating Profit (PBDIT) excl Other Income
89.40
131.20
-31.86%
Interest
2.10
14.90
-85.91%
Exceptional Items
16.10
18.70
-13.90%
Consolidate Net Profit
94.00
75.10
25.17%
Operating Profit Margin (Excl OI)
220.60%
233.80%
-1.32%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 0.57% vs 12.13% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 25.17% vs -23.91% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,389.80
2,311.20
3.40%
Operating Profit (PBDIT) excl Other Income
743.60
675.50
10.08%
Interest
48.10
60.40
-20.36%
Exceptional Items
67.50
105.10
-35.78%
Consolidate Net Profit
647.50
581.40
11.37%
Operating Profit Margin (Excl OI)
251.90%
231.50%
2.04%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.40% vs 14.49% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 11.37% vs 0.38% in Dec 2024
About Tibet Cheezheng Tibetan Medicine Co., Ltd. 
Tibet Cheezheng Tibetan Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






